Alpha-Particle Radioactive Nanocapsules Provide New Weapon for Fighting Cancer

Food and Drug Administration]-approved cancer therapies that employ alpha-particle radiation,” said lead researcher Dr. Lon Wilson, professor of chemistry at Rice University (Houston, TX, USA). "Approved therapies that use beta particles are not well-suited for treating cancer at the single-cell level because it takes thousands of beta particles to kill a lone cell. By contrast, cancer cells can be destroyed with just one direct hit from an alpha particle on a cell nucleus.”

In the study, Dr. Wilson, Rice graduate student Keith Hartman, University of Washington (UW; Seattle, WA, USA) radiation oncologist Dr. Scott Wilbur and UW research scientist Dr. Donald Hamlin, devised and evaluated a process to load astatine atoms inside short sections of carbon nanotubes. Because astatine is the rarest naturally occurring element on Earth--with less than a teaspoon estimated to exist in the Earth's crust at any given time--the study was done using astatine created in a UW cyclotron.

Astatine, similar to radium and uranium, emits alpha particles via radioactive decay. Alpha particles, which contain two protons and two neutrons, are the most massive particles emitted as radiation. They are approximately 4,000 times bigger than the electrons emitted by beta decay--the type of radiation most typically used to treat cancer. "It's something like the difference between a cannon shell and a BB,” Dr. Wilson said. "The extra mass increases the amount of damage alpha particles can inflict on cancer cells.”

The speed of radioactive particles is also an important factor in medical use. Beta particles travel very quickly. This, combined with their small size, gives them considerable penetrating strength. In cancer treatment, for example, beams of beta particles can be generated outside the patient's body and directed at tumors. Alpha particles move much more slowly, and because they are also massive, they have very little penetrating power. They can be stopped by something as flimsy as tissue paper.

"The unique combination of low penetrating power and large particle mass make alpha particle ideal for targeting cancer at the single-cell level,” Dr. Wilson said. "The difficulty in developing ways to use them to treat cancer has come in finding ways to deliver them quickly and directly to the cancer site.”

In earlier research, Dr. Wilson and colleagues developed techniques to attach antibodies to carbon fullerenes similar to the nanotubes. Antibodies are proteins produced by white blood cells. Each antibody is designed to recognize and bind only with a specific antigen, and researchers have identified a variety of cancer-specific antibodies that can be utilized to kill cancer cells.

In follow-up studies, Dr. Wilson hopes to assess the single-celled cancer targeting approach by attaching cancer-specific antibodies to astatine-loaded nanotubes. The carbon nanotubes used in the study were provided by Carbon Nanotechnologies, Inc. (Houston, TX, USA).

One problematic factor in any astatine-based cancer therapy will be the element's short, 7.5-hour half-life. In radioactive decay, the term half-life refers to the time required for any quantity of a substance to decay by half its initial mass. Due to astatine's brief half-life, any treatment must be delivered in a timely way, before the particles lose their potency.

The study's findings were made available in the online issue of the journal Small in August 2007.


Related Links:
Rice University
University of Washington